Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss

Related Clinical Trial
The Performance of a Robot-assisted Minimally Invasive Direct Cochlear Access for Cochlear Implantation Auditory Performances With Different Stimulation Depths in Cochlear Implanted Subjects Using a Fine Structure Strategy Feasibility of the Mi2000 Totally Implantable Cochlear Implant in Severely to Profoundly Deaf Adults. Hearing Aid Noise Reduction in Pediatric Users Pilot Study (Oticon Pilot Study) Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss Dexamethasone-Eluting Cochlear Implant Electrode Artificial Intelligence in Diagnosis of DFNA9 Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC Cochlear Implant and Vestibular Function. Quality Control of CE-Certified Phonak Hearing Aids – 2018_42 Quality Control of CE-Certified Phonak Hearing Aids – 2018_28 Enlarged Vestibular Aqueduct Registry Evaluation of the High Frequency Digit Triplet Test in Cystic Fibrosis Effectiveness of P02 Digital Hearing Aids ABR Characteristics and Salivary Cortisone Concentration in Noise-exposed Workers Clinical Investigation of New CI Delivery Models in an Adult Nucleus CI Population Genetic Analysis of Hereditary Disorders of Hearing and Balance Compassionate Use Arm – ABI541 ABI for 10 NF2 Patients Evaluation of a Binaural Beamformer (StereoZoom) in a Virtual Acoustic Environment and in Real Life Evaluation of N6 Sound Processor in Group of Freedom Users Robotic Assisted Cochlear Implantation Feasibility Study Auditory Nerve Test System During Vestibular Schwannoma Resection Cochlear Electrical Impedance and the Effect of Topical Dexamethasone on Cochlear Implant Surgery Comparison Between Neuro 1 and Neuro 2 Cochlear Implant Speech Processors Listening Effort in Cochlear Implant Users Quality Control of CE-Certified Phonak Hearing Aids – 2019_19 Esteem Totally Implantable Hearing System A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease Study of Quality Perception on Music in New Cochlear Implanted Subjects Using or Not a Fine Structure Strategy An Evidence Based Delivery Model of Care for Newly Implanted Adult CI Recipients Study of Auditory Performance on Prosodic Tests in Cochlear Implanted Subjects Using a Fine Structure Strategy CI532 – Early Experience Study Clinical Applications of Round Window Imaging Anatomy in Cochlear Implant Surgery Single-sided Deafness and Cochlear Implants Cochlear Implantation Among Adults and Older Children With Unilateral or Asymmetric Hearing Loss Clinal Evaluation of Navigation Based Functional Ear Surgery Using Image Guided and Robotically Assisted Techniques OTO-413 in Subjects With Speech-in-Noise Hearing Impairment The Efficacy of a Minimally Invasive Direct Cochlear Access Via the HEARO Procedure Clinical Evaluation of a Cochlear Implant System Objective Measures in Cochlear Implant Evaluation of a Binaural Spatialization Method for Hearing Aids Esteem New Subject Enrollment Post Approval Study Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss Investigation of Anatomical Correlates of Speech Discrimination Efficacy of Digital Noise Reduction Strategies: A Hearing Aid Trial Evaluation of Revised Indicatons (ERID) for Cochlear Implant Candidacy for the Adult CMS Population Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts Balance in Children With Cochlear Implants Congenital Cytomegalovirus: Efficacy of Antiviral Treatment Nucleus Freedom Cochlear Implant System Pediatric Post-approval Study Evaluation of the Nucleus Hybrid™ L24 Cochlear Implant System Radiological Classification of the Facial Nerve Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial The Effect of Sound Stimulation on Hearing Ability The Effect of Sound Stimulation on Pure-tone Hearing Threshold Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss The SeaSHeL National Prospective Cohort Study Non-linear Frequency Compared to Conventional Processing in Patients With and Without Cochlear Dead Regions. Study of Low Level Laser Therapy and Word Recognition in Hearing Impaired Individuals Electrode Placement and Audiologic Outcomes With the Advanced Bionics HiFocus L23 Electrode Video HIT in Sudden Sensorineural Hearing Loss Determine the Incidence of Long QT Amongst a Large Cohort of Subjects Diagnosed With Unilateral or Bilateral Sensorineural Hearing Loss. FX-322 in Sensorineural Hearing Loss Autologous Bone Marrow Harvest and Transplant for Sensorineural Hearing Loss FX-322 in Adults With Stable Sensorineural Hearing Loss

Brief Title

Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss

Official Title

A Two-part, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of SENS-401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss

Brief Summary

      Primary objective of the study is to assess the efficacy of SENS-401 on hearing loss in
      comparison to placebo at the end of the 4-week treatment period
    

Detailed Description

      Patients will receive the study drug (SENS-401 or placebo) in the form of tablets by mouth,
      twice a day (3 tablets in the morning and 3 tablets in the evening), during the first 4 weeks
      after randomization.

      SENS-401 is an investigational medicinal product. It belongs to a family of drugs known as "5
      HT3 antagonist".
    

Study Phase

Phase 2/Phase 3

Study Type

Interventional


Primary Outcome

Change in pure tone audiometry PTA (dB)


Condition

Severe Sudden Sensorineural Hearing Loss

Intervention

SENS-401

Study Arms / Comparison Groups

 29 mg dose group
Description:  Patients will receive the study drug (SENS-401) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

458

Start Date

February 15, 2019

Completion Date

August 30, 2022

Primary Completion Date

June 30, 2021

Eligibility Criteria

        The main criteria for inclusion:

          -  Male or female aged at least 18 years old

          -  Patients with unilateral idiopathic sudden sensorineural hearing loss or
             unilateral/bilateral acute acoustic trauma leading to sudden sensorineural hearing
             loss.

          -  Patients with sudden hearing loss with onset within 96 hours prior to prior to first
             study drug intake.

          -  Patients under highly effective contraception

        The main criteria for exclusion:

          -  Bilateral idiopathic hearing loss

          -  Fluctuating hearing loss

          -  History of asymmetric hearing (>20 dB difference between ears) to the best knowledge
             of the patient

          -  Severe hearing loss (>90 dB) associated with unilateral (ipsilateral) complete
             vestibular loss.

          -  History of Ménière's disease, autoimmune hearing loss, radiation-induced hearing loss,
             acoustic neuroma (schwannoma), otosclerosis, suspected perilymph fistula or membrane
             rupture, suspected retro-cochlear lesion, or barotrauma

          -  Previous SSNHL in the affected ear within the past 6 weeks

          -  Complete loss of peripheral vestibular function on the affected side

          -  Any drug-based therapy for inner ear hearing loss that is ongoing or was performed in
             the past 6 weeks (except oral corticosteroids)

          -  Any ongoing or planned concomitant medication for the treatment of tinnitus until 6
             weeks after administration.

          -  Any therapy known as ototoxic (e.g. aminoglycosides, cisplatin, loop diuretics,
             quinine etc.) at the current time or in the past 6 months or planned in the coming 3
             months.

          -  Acute or chronic otitis media or otitis externa terminated less than 7 days

          -  Prior ear surgery of any kind (except ventilating tubes), or cochlear implants

          -  Known history of, or concomitant severe hepatic, gastrointestinal, cardiovascular,
             respiratory, neurological (except vertigo or tinnitus), hematological, renal,
             dermatological or psychiatric disease or substance abuse

          -  Neurological disorders including stroke, demyelinating disease, brain stem or
             cerebellar dysfunction within the last 3 months.

          -  Treatment with any investigational agent within 4 weeks or any past treatment with
             azasetron or with 5-HT3 antagonists, or any prior or planned treatment by
             antidepressant treatment containing serotoninergic agents.

          -  Patients with either a history of significant arrhythmia, or a history of conditions
             known to increase the proarrhythmic risk (e.g., congestive heart failure, long QT
             Syndrome, hypokalemia etc...).
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Géraldine HONNET, MD, +33(0)786676542, [email protected]

Location Countries

France

Location Countries

France

Administrative Informations


NCT ID

NCT03603314

Organization ID

SENS 401-201


Responsible Party

Sponsor

Study Sponsor

Sensorion


Study Sponsor

Géraldine HONNET, MD, Study Director, Sensorion


Verification Date

October 2020